Ionis Pharma rises after lifting 2025 revenue forecast
30/04/2025 14:37
** Shares of drugmaker Ionis Pharmaceuticals IONS.O rise 6% to $31.65 ** IONS ups 2025 sales forecast to $725 mln to $750 mln, up from prior forecast of at least $600 mln; analysts were expecting 2025 sales to be $659.7 mln - LSEG ** IONS posts Q1 sales of $132 mln vs analysts' est of $125.3 mln - LSEG ** IONS reports Q1 loss of 93 cents, compared with a loss of 98 cents a year ago ** As of last close, stock down 14.7% YTD (Reporting by Kamal Choudhury in Bengaluru) ((Kamal.Choudhury@thomsonreuters.com;))
Recent news on Ionis Pharmaceuticals
See all newsAnalysis: US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
Brief: Ionis Announces License Agreement With Recordati For Zilganersen In Alexander Disease (Axd) In All Countries Outside The U.S.
Brief: Ionis Pharmaceuticals Says FDA Approved Tryngolza For Severe Hypertriglyceridemia
Brief: FDA Approves Treatment To Reduce Risk Of Acute Pancreatitis In Adults With Severe Hypertriglyceridemia
Brief: Ionis Announces Appointment Of Ludwig Hantson, Ph.D. To Board Of Directors